Statins have been linked to insulin resistance and the subsequent development of diabetes; however, Inclisiran’s targeted mechanism offers a promising advantage by focusing on PCSK9, thereby bypassing multiple metabolic pathways and suggesting a lower risk of interference with glucose metabolism [16,17,32]. This evidence concerns the gene PCSK9 and Insulin resistance.